Geron Corporation
GERN
Positions held
Your positionsGERN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $783.82M | Enterprise value | $605.11M | Trailing P/E | — | Forward P/E | 30.50 |
| PEG | — | Price / book | 3.59 | Beta | 0.61 | Dividend yield | 0.00% |
| Revenue growth | 17.2% | Earnings growth | — | Gross margin | 58.5% | Operating margin | -22.0% |
| Profit margin | -33.1% | ROE | -28.3% | ROA | -4.1% | Debt / equity | 0.56 |
| Current ratio | 6.92 | Free cash flow | -$78.37M | Analyst recommendation | none | Mean target | $4.25 |
| 52w high | $2.01 | 52w low | $1.04 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $57.5M | $51.8M | $48.0M | $47.2M | $49.0M | — |
| Op margin | -22.0% | -0.5% | -17.7% | -29.4% | -25.4% | — |
| Net income | -$16.7M | -$3.6M | -$28.9M | -$18.4M | -$16.4M | — |
| Gross margin | 83.9% | 96.7% | 97.3% | 97.8% | 97.6% | — |
| Gross profit | $48.2M | $50.1M | $46.7M | $46.2M | $47.8M | — |
| Operating income | -$12.7M | -$0.2M | -$8.5M | -$13.9M | -$12.5M | — |
- Revenue +11% vs prior quarter ($57M vs $52M).
- Gross margin 83.9% (was 96.7% prior quarter).
- Operating margin compressed to -22%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $184M | $77.0M | $0.2M | $0.6M | — |
| Op margin | -28.0% | -225.6% | -81832.9% | -23246.6% | — |
| Net income | -$83.5M | -$175M | -$184M | -$142M | — |
| Gross margin | 97.4% | 98.4% | 100.0% | 100.0% | — |
| Gross profit | $179M | $75.7M | $0.2M | $0.6M | — |
| Operating income | -$51.6M | -$174M | -$194M | -$139M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
2026-09-18 · Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-16 · Geron Eyes High End of 2026 RYTELO Revenue Guidance as Community Adoption Expands
2026-09-13 · Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
2026-09-02 · Geron to Present at Upcoming Investor Conferences
2026-08-18 · Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-10 · Geron (GERN) Stock Looks Reasonable On Sales But Weak On Returns
2026-08-09 · Geron (GERN) Back In Focus As Fresh Guidance And Earnings Test Its Undervalued Narrative
2026-08-09 · Geron (GERN) Is Up 14.7% After Issuing First RYTELO Revenue Guide And Narrowing Losses - Has The Bull Case Changed?
2026-08-06 · Geron (GERN) Q2 2026 Earnings Call Transcript
2026-08-05 · Geron Corp (GERN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...
2026-08-05 · Geron Corporation Q2 2026 Earnings Call Summary
Price (daily)
Full chart · RSI · MACD · patterns